39 results on '"Beca F"'
Search Results
2. 930TiP innovaTV 207: New dosing cohort in the open label phase II study of tisotumab vedotin in solid tumors
- Author
-
Hong, D., primary, Fayette, J., additional, Birnbaum, A., additional, Steuer, C., additional, Taylor, M.H., additional, George, T.J., additional, Lacy, J., additional, Beca, F., additional, Nicacio, L.V., additional, Soumaoro, I., additional, and Cho, M., additional
- Published
- 2021
- Full Text
- View/download PDF
3. Metastatic breast cancer: mechanisms and opportunities for cytology
- Author
-
Martins, D., Beca, F., and Schmitt, F.
- Published
- 2014
- Full Text
- View/download PDF
4. Ciudadanía y migración. ¿Son compatibles?
- Author
-
Beca F.,Juan Pablo
- Subjects
Ciudadanía ,Inmigración ,Sufragio - Abstract
Resumen Los derechos políticos de los migrantes son un tema poco explorado, limitándose el desarrollo legislativo y jurisprudencial al derecho a sufragio, que es sólo un aspecto de los derechos ciudadanos. Existe la tendencia a reconocer este derecho a extranjeros en elecciones de carácter local (con obvias diferencias entre los diversos países), pero no se ha avanzado en su verdadera integración al cuerpo político. Se hace necesario repensar los conceptos de nacionalidad y ciudadanía, como un imperativo para mejorar la calidad de la democracia, respetar los derechos humanos y terminar con legislaciones y políticas discriminatorias. De este modo, se puede aportar a una integración de los migrantes a la comunidad nacional. Para ello, se propone conceder la ciudadanía, separada de la nacionalidad, a inmigrantes que cumplan con ciertos requisitos.
- Published
- 2019
5. LEGALIDAD Y LEGITIMIDAD CARL SCHMITT.
- Author
-
Juan Pablo Beca F.
- Subjects
Anthropology ,GN1-890 ,Sociology (General) ,HM401-1281 - Abstract
TRADUCCIÓN DE CRISTINA MONEREO ATIENZA. EDITORIAL COMARES, S.L., GRANADA, 2006
- Published
- 2007
- Full Text
- View/download PDF
6. Ciudadanía y migración. ¿Son compatibles?
- Author
-
Beca F., Juan Pablo, primary
- Published
- 2019
- Full Text
- View/download PDF
7. Abstract P5-11-06: Does hormone expression by IHC predict ER pathway activity? An analysis in a metastatic breast cancer patient cohort
- Author
-
Yang, S-R, primary, van de Stolpe, A, additional, van Brussel, A, additional, van Ooijen, H, additional, Galimzianova, A, additional, Cohn, DM, additional, Beca, F, additional, Rubin, DL, additional, and Allison, KH, additional
- Published
- 2019
- Full Text
- View/download PDF
8. Abstract P2-07-07: Development of a machine learning-based classifier for Oncotype DX® category prediction in a population of lymph node positive breast carcinoma patients
- Author
-
Beca, F, primary, Yang, S-R, additional, Gruber, JG, additional, Barry-Holson, K, additional, West, R, additional, Wen, HY, additional, and Allison, KH, additional
- Published
- 2019
- Full Text
- View/download PDF
9. Quantifying chromosomal copy number alterations in breast ductal carcinoma in situ: A deep learning based approach
- Author
-
Sirinukunwattana, K., primary, Lin, J., additional, Lu, P., additional, Beca, F., additional, Peng, J., additional, Tolwani, A., additional, Stancu, A., additional, Varma, S., additional, and West, R., additional
- Published
- 2018
- Full Text
- View/download PDF
10. LEGALIDAD Y LEGITIMIDAD CARL SCHMITT.
- Author
-
Beca F., Juan Pablo, primary
- Published
- 2012
- Full Text
- View/download PDF
11. Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast.
- Author
-
da Silva EM, Beca F, Sebastiao APM, Murray MP, Silveira C, Da Cruz Paula A, Pareja F, Wen HY, D'Alfonso TM, Edelweiss M, Weigelt B, Brogi E, Reis-Filho JS, and Zhang H
- Subjects
- Adult, Aged, Aged, 80 and over, Biopsy, Breast Neoplasms pathology, Class I Phosphatidylinositol 3-Kinases genetics, DNA Mutational Analysis, Exons, Female, Fibroadenoma pathology, Genetic Predisposition to Disease, Humans, Middle Aged, Phenotype, Stromal Cells pathology, Telomerase genetics, Biomarkers, Tumor genetics, Breast Neoplasms genetics, Fibroadenoma genetics, Mediator Complex genetics, Mutation
- Abstract
Aims: Here we explore the presence of mediator complex subunit 12 ( MED12 ) exon 2 and telomerase reverse transcriptase ( TERT ) promoter hotspot mutations in complex fibroadenomas (CFAs) of the breast., Methods: The stromal components from 18 CFAs were subjected to Sanger sequencing of MED12 exon 2 and the TERT promoter hotspot loci. The epithelial and stromal components of two MED12 mutated CFAs were subjected to laser capture microdissection, and Sanger sequencing of MED12 exon 2, TERT promoter and PIK3CA exons 9 and 20, separately., Results: MED12 exon 2 mutations were identified in the stroma of 17% of CFAs. The analyses of epithelial and stromal components, microdissected separately, revealed that MED12 mutations were restricted to the stroma. No TERT promoter or PIK3CA mutations in exons 9 and 20 were detected in analysed CFAs., Conclusions: Like conventional fibroadenomas, MED12 exon 2 mutations appear to be restricted to the stromal component of CFAs, supporting the notion that CFAs are stromal neoplasms., Competing Interests: Competing interests: JSR-F reports receiving personal/consultancy fees from Goldman Sachs and REPARE Therapeutics, membership of the scientific advisory boards of VolitionRx, REPARE Therapeutics and Paige. AI, membership of the Board of Directors of Grupo Oncoclinicas, and ad hoc membership of the scientific advisory boards of Roche Tissue Diagnostics, Ventana Medical Systems, Novartis, Genentech and InVicro, outside the scope of this study. HZ reports consultancy fee from Roche/Genentech, outside the scope of the submitted work. FB is currently an employee and equity holder of Seattle Genetics, Inc but the present work is outside the scope of his role., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
12. Molecular analysis of TCGA breast cancer histologic types.
- Author
-
Thennavan A, Beca F, Xia Y, Recio SG, Allison K, Collins LC, Tse GM, Chen YY, Schnitt SJ, Hoadley KA, Beck A, and Perou CM
- Abstract
Breast cancer is classified into multiple distinct histologic types, and many of the rarer types have limited characterization. Here, we extend The Cancer Genome Atlas Breast Cancer (TCGA-BRCA) dataset with additional histologic type annotations, in a total of 1063 breast cancers. We analyze this extended dataset to define transcriptomic and genomic profiles of six rare special histologic types: cribriform, micropapillary, mucinous, papillary, metaplastic, and invasive carcinoma with medullary pattern. We show the broader applicability of our constructed special histologic type gene signatures in the TCGA Pan-Cancer Atlas dataset with a predictive model that detects mucinous histologic type across cancers of other organ systems. Using a normal mammary cell differentiation score analysis, we order histologic types into a continuum from stem cell-like to luminal progenitor-like to mature luminal-like. Finally, we classify TCGA-BRCA into 12 consensus groups based on integrated genomic and histological features. We present a rich openly accessible resource of histologic and genomic characterization of TCGA-BRCA to enable studies of the range of breast cancers.
- Published
- 2021
- Full Text
- View/download PDF
13. The impact of mammographic screening on the subsequent breast cancer risk associated with biopsy-proven benign breast disease.
- Author
-
Beca F, Oh H, Collins LC, Tamimi RM, and Schnitt SJ
- Abstract
Data on the risk of breast cancer following a benign breast disease (BBD) diagnosis were derived predominantly from populations of women biopsied before the widespread use of mammographic screening and in whom these lesions were mostly incidental findings. Whether or not similar risk associations are seen when these lesions are detected in mammographically screened populations is unknown. To address this, we examined the variation in BBD and breast cancer risk associations by the calendar time of BBD diagnosis (pre- vs. post-mammography era [before vs. 1985 and after]) in a nested case-control study within the Nurses' Health Study (NHS) and NHSII BBD subcohort (488 cases; 1908 controls). We performed logistic regression analysis, adjusting for matching factors and potential confounders, to estimate odds ratio (ORs) and 95% confidence interval (CI) for the association between BBD subtype (non-proliferative, proliferative without atypia, proliferative with atypical hyperplasia (AH)) and subsequent breast cancer risk. When compared with non-proliferative lesions, both proliferative lesions without atypia (PWA) and AHs were associated with similar levels of risk in the pre-mammographic (pre) and post-mammographic (post) time periods (PWA: OR [95% CI] = 1.73 [1.27, 2.36] pre vs. 1.12 [0.73, 1.74] post; AH: 4.41 [2.90, 6.70] pre vs. 3.69 [2.21, 6.15] post). The interaction by mammography era was not statistically significant (p-interaction = 0.47). These results suggest that the risk associations reported for BBD subtypes in the pre-mammography era remain valid for BBD detected after the widespread implementation of mammographic screening.
- Published
- 2021
- Full Text
- View/download PDF
14. The genomic landscape of metastatic histologic special types of invasive breast cancer.
- Author
-
Pareja F, Ferrando L, Lee SSK, Beca F, Selenica P, Brown DN, Farmanbar A, Da Cruz Paula A, Vahdatinia M, Zhang H, Zoppoli G, Wen HY, Brogi E, Robson ME, Razavi P, Chandarlapaty S, Weigelt B, and Reis-Filho JS
- Abstract
Histologic special types of breast cancer (BC) account for ~20% of BCs. Large sequencing studies of metastatic BC have focused on invasive ductal carcinomas of no special type (IDC-NSTs). We sought to define the repertoire of somatic genetic alterations of metastatic histologic special types of BC. We reanalyzed targeted capture sequencing data of 309 special types of BC, including metastatic and primary invasive lobular carcinomas (ILCs; n = 132 and n = 127, respectively), mixed mucinous ( n = 5 metastatic and n = 14 primary), micropapillary ( n = 12 metastatic and n = 8 primary), and metaplastic BCs ( n = 6 metastatic and n = 5 primary), and compared metastatic histologic special types of BC to metastatic IDC-NSTs matched according to clinicopathologic characteristics and to primary special type BCs. The genomic profiles of metastatic and primary special types of BC were similar. Important differences, however, were noted: metastatic ILCs harbored a higher frequency of genetic alterations in TP53 , ESR1 , FAT1 , RFWD2 , and NF1 than primary ILCs, and in CDH1 , PIK3CA , ERBB2 , TBX3 , NCOR1 , and RFWD2 than metastatic IDC-NSTs. Metastatic ILCs displayed a higher mutational burden, and more frequently dominant APOBEC mutational signatures than primary ILCs and matched metastatic IDC-NSTs. ESR1 and NCOR mutations were frequently detected in metastatic mixed mucinous BCs, whereas PIK3CA and TP53 were the most frequently altered genes in metastatic micropapillary and metaplastic BCs, respectively. Taken together, primary and metastatic BCs histologic special types have remarkably similar repertoires of somatic genetic alterations. Metastatic ILCs more frequently harbor APOBEC mutational signatures than primary ILCs and metastatic IDC-NSTs., Competing Interests: Competing interestsJ.S.R.-F. reports receiving personal/consultancy fees from Goldman Sachs and REPARE Therapeutics, membership of the scientific advisory boards of VolitionRx and Page.AI, and ad hoc membership of the scientific advisory boards of Roche Tissue Diagnostics, Ventana Medical Systems, Novartis, Genentech and InVicro, outside the scope of this study. P.R. reports consulting/advisory board for Novartis and institutional research support from Illumina and GRAIL, Inc. S.C. has received research support from Daichi Sankyo and consulting fees from Novartis, Sermonix, BMS, Context Therapeutics, Revolution Medicine, Paige AI, and Eli Lilly. G.Z. has received research support from ThermoFisher Scientific, AstraZeneka UK, and SIDRA Medicine. All other authors declare no competing interests., (© The Author(s) 2020.)
- Published
- 2020
- Full Text
- View/download PDF
15. Whole-exome analysis of metaplastic breast carcinomas with extensive osseous differentiation.
- Author
-
Beca F, Sebastiao APM, Pareja F, Dessources K, Lozada JR, Geyer F, Selenica P, Zeizafoun N, Wen HY, Norton L, Brogi E, Weigelt B, and Reis-Filho JS
- Subjects
- Biomarkers, Tumor genetics, Breast Neoplasms pathology, Female, Gene Expression Regulation, Neoplastic, Humans, Mutation, Oncogene Protein v-akt genetics, Oncostatin M Receptor beta Subunit genetics, Signal Transduction genetics, TOR Serine-Threonine Kinases genetics, Tumor Suppressor Protein p53 genetics, Phosphatidylinositol 3-Kinases genetics, Triple Negative Breast Neoplasms genetics, Triple Negative Breast Neoplasms metabolism, Exome Sequencing
- Abstract
Aims: Metaplastic breast carcinoma (MBC) is a rare type of triple-negative breast cancer that shows vast histological and genetic heterogeneity. Osseous differentiation can be found in different subtypes of MBC. Whether MBCs with osseous differentiation are underpinned by specific genetic alterations has yet to be defined. The aim of this study was to investigate the repertoire of somatic mutations and copy number alterations (CNAs) in three MBCs with extensive osseous differentiation., Methods and Results: Tumour and normal DNA samples from three MBCs with extensive osseous differentiation were subjected to whole-exome sequencing. Somatic mutations, CNAs and mutational signatures were determined by use of a validated bioinformatics pipeline. Our analyses revealed clonal TP53 hotspot mutations associated with loss of heterozygosity of the wild-type allele coupled with mutations affecting genes related to the Wnt and/or the phosphoinositide 3-kinase-AKT-mammalian target of rapamycin pathways in all cases analysed. All cases showed a dominant mutational signature 1, with two cases showing a secondary signature 3 in addition to other features of homologous recombination DNA repair defects. The oncostatin M receptor gene, which plays a role in mesenchymal differentiation and bone formation, was found to be mutated in two MBCs with extensive osseous differentiation and in none of 35 previously published 35 MBCs., Conclusion: Our findings suggest that MBCs with osseous differentiation have somatic mutations similar to those of other forms of MBC., (© 2020 John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
16. Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis.
- Author
-
Beca F, Krings G, Chen YY, Hosfield EM, Vohra P, Sibley RK, Troxell ML, West RB, Allison KH, and Bean GR
- Subjects
- Adult, Female, Humans, Middle Aged, Mutation, Breast Neoplasms genetics, Class I Phosphatidylinositol 3-Kinases genetics, Hemangiosarcoma genetics, Vascular Endothelial Growth Factor Receptor-2 genetics
- Abstract
Angiosarcoma (AS) is the most frequent primary sarcoma of the breast but nevertheless remains uncommon, accounting for <0.05% of breast malignancies. Secondary mammary AS arise following radiation therapy for breast cancer, in contrast to primary AS which occur sporadically. Essentially all show aggressive clinical behavior independent of histologic grade and most are treated by mastectomy. MYC amplification is frequently identified in radiation-induced AS but only rarely in primary mammary AS (PMAS). As a heterogeneous group, AS from various anatomic sites have been shown to harbor recurrent alterations in TP53, MAP kinase pathway genes, and genes involved in angiogenic signaling including KDR (VEGFR2) and PTPRB. In part due to its rarity, the pathogenesis of PMAS has not been fully characterized. In this study, we examined the clinical, pathologic, and genomic features of ten cases of PMAS, including one patient with bilateral disease. Recurrent genomic alterations were identified in KDR (70%), PIK3CA/PIK3R1 (70%), and PTPRB (30%), each at higher frequencies than reported in AS across all sites. Six tumors harbored a KDR p.T771R hotspot mutation, and all seven KDR-mutant cases showed evidence suggestive of biallelism (four with loss of heterozygosity and three with two aberrations). Of the seven tumors with PI3K alterations, six harbored pathogenic mutations other than in the canonical PIK3CA residues which are most frequent in breast cancer. Three AS were hypermutated (≥10 mutations/megabase (Mb)); hypermutation was seen concurrent with KDR or PIK3CA mutations. The patient with bilateral disease demonstrated shared alterations, indicative of contralateral metastasis. No MYC or TP53 aberrations were detected in this series. Immunohistochemistry for VEGFR2 was unable to discriminate between KDR-mutant tumors and benign vascular lesions of the breast. These findings highlight the underrecognized frequency of KDR and PIK3CA mutation in PMAS, and a significant subset with hypermutation, suggesting a pathogenesis distinct from other AS.
- Published
- 2020
- Full Text
- View/download PDF
17. Whole-exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast.
- Author
-
Beca F, Lee SSK, Pareja F, Da Cruz Paula A, Selenica P, Ferrando L, Gularte-Mérida R, Wen HY, Zhang H, Guerini-Rocco E, Rakha EA, Weigelt B, and Reis-Filho JS
- Subjects
- Breast pathology, Breast Neoplasms pathology, Carcinoma, Acinar Cell pathology, DNA Damage, DNA Mutational Analysis, DNA Repair, Female, High-Throughput Nucleotide Sequencing, Humans, Mutation, Sequence Analysis, RNA, Triple Negative Breast Neoplasms pathology, Exome Sequencing, BRCA1 Protein genetics, Breast Neoplasms genetics, Carcinoma, Acinar Cell genetics, DNA Copy Number Variations, Triple Negative Breast Neoplasms genetics, Tumor Suppressor Protein p53 genetics
- Abstract
Aims: Acinic cell carcinoma (ACC) of the breast is a rare histological form of triple-negative breast cancer (TNBC). Despite its unique histology, targeted sequencing analysis has failed to identify recurrent genetic alterations other than those found in common forms of TNBC. Here we subjected three breast ACCs to whole-exome and RNA sequencing to determine whether they would harbour a pathognomonic genetic alteration., Methods and Results: DNA and RNA samples from three breast ACCs were subjected to whole-exome sequencing and RNA-sequencing, respectively. Somatic mutations, copy number alterations, mutational signatures and fusion genes were determined with state-of-the-art bioinformatics methods. Our analyses revealed TP53 hotspot mutations associated with loss of heterozygosity of the wild-type allele in two cases. Mutations affecting homologous recombination DNA repair-related genes were found in two cases, and an MLH1 pathogenic germline variant was found in one case. In addition, copy number analysis revealed the presence of a somatic BRCA1 homozygous deletion and focal amplification of 12q14.3-12q21.1, encompassing MDM2, HMGA2, FRS2, and PTPRB. No oncogenic in-frame fusion transcript was identified in the three breast ACCs analysed., Conclusions: No pathognomonic genetic alterations were detected in the breast ACCs analysed. These tumours have somatic genetic alterations similar to those of common forms of TNBC, and may show homologous recombination deficiency or microsatellite instability. These findings provide further insights into why breast ACCs, which are usually clinically indolent, may evolve into or in parallel with high-grade TNBC., (© 2019 John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
18. Outcome of radial scar/complex sclerosing lesion associated with epithelial proliferations with atypia diagnosed on breast core biopsy: results from a multicentric UK-based study.
- Author
-
Rakha E, Beca F, D'Andrea M, Abbas A, Petrou-Nunn W, Shaaban AM, Kandiyil A, Smith S, Menon S, Elsheikh S, ElSayed ME, Lee AH, and Sharma N
- Subjects
- Adult, Aged, Biopsy, Large-Core Needle, Diagnosis, Differential, England, Female, Humans, Middle Aged, Neoplasm Grading, Predictive Value of Tests, Retrospective Studies, Breast pathology, Breast Neoplasms pathology, Carcinoma, Intraductal, Noninfiltrating pathology, Cell Proliferation, Epithelial Cells pathology, Fibrocystic Breast Disease pathology
- Abstract
Aims: The clinical significance of radial scar (RS)/complex sclerosing lesion (CSL) with high-risk lesions (epithelial atypia) diagnosed on needle core biopsy is not well defined. We aimed at assessing the upgrade rate to ductal carcinoma in situ (DCIS) and invasive carcinoma on the surgical excision specimen in a large cohort with RS/CSL associated with atypia., Methods: 157 women with a needle core biopsy diagnosis of a RS/CSL with atypia and follow-up histology were studied. Histological findings, including different forms of the atypical lesions and final histological outcome in the excision specimens, were retrieved and analysed, and the upgrade rates for malignancy and for invasive carcinoma were calculated., Results: 69.43% of the cases were associated with atypical ductal hyperplasia (ADH) or atypia not otherwise classifiable, whereas lobular neoplasia was seen in 21.66%. On final histology, 39 cases were malignant (overall upgrade rate of 24.84%); 12 were invasive and 27 had DCIS. The upgrade differed according to the type of atypia and was highest for ADH (35%). When associated with lobular neoplasia, the upgrade rate was 11.76%. The upgrade rate's variability was also considerably lower when considering the upgrade to invasive carcinoma alone for any associated lesion., Conclusions: The upgrade rate for ADH diagnosed on needle core biopsy with RS is similar to that of ADH without RS and therefore should be managed similarly. RS associated with lobular neoplasia is less frequently associated with malignant outcome. Most lesions exhibiting some degree of atypia showed a similar upgrade rate to invasive carcinoma. Management of RS should be based on the concurrent atypical lesion., Competing Interests: Competing interests: None., (© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2019
- Full Text
- View/download PDF
19. EN1 Is a Transcriptional Dependency in Triple-Negative Breast Cancer Associated with Brain Metastasis.
- Author
-
Peluffo G, Subedee A, Harper NW, Kingston N, Jovanović B, Flores F, Stevens LE, Beca F, Trinh A, Chilamakuri CSR, Papachristou EK, Murphy K, Su Y, Marusyk A, D'Santos CS, Rueda OM, Beck AH, Caldas C, Carroll JS, and Polyak K
- Subjects
- Brain Neoplasms genetics, Brain Neoplasms mortality, Co-Repressor Proteins genetics, Co-Repressor Proteins metabolism, Female, Gene Expression Regulation, Neoplastic, Humans, MCF-7 Cells, Prognosis, Transcription Factors genetics, Triple Negative Breast Neoplasms genetics, Xenograft Model Antitumor Assays, Brain Neoplasms secondary, Homeodomain Proteins genetics, Triple Negative Breast Neoplasms mortality, Triple Negative Breast Neoplasms pathology
- Abstract
To define transcriptional dependencies of triple-negative breast cancer (TNBC), we identified transcription factors highly and specifically expressed in primary TNBCs and tested their requirement for cell growth in a panel of breast cancer cell lines. We found that EN1 (engrailed 1) is overexpressed in TNBCs and its downregulation preferentially and significantly reduced viability and tumorigenicity in TNBC cell lines. By integrating gene expression changes after EN1 downregulation with EN1 chromatin binding patterns, we identified genes involved in WNT and Hedgehog signaling, neurogenesis, and axonal guidance as direct EN1 transcriptional targets. Quantitative proteomic analyses of EN1-bound chromatin complexes revealed association with transcriptional repressors and coactivators including TLE3, TRIM24, TRIM28, and TRIM33. High expression of EN1 correlated with short overall survival and increased risk of developing brain metastases in patients with TNBC. Thus, EN1 is a prognostic marker and a potential therapeutic target in TNBC. SIGNIFICANCE: These findings show that the EN1 transcription factor regulates neurogenesis-related genes and is associated with brain metastasis in triple-negative breast cancer., (©2019 American Association for Cancer Research.)
- Published
- 2019
- Full Text
- View/download PDF
20. Predicting breast tumor proliferation from whole-slide images: The TUPAC16 challenge.
- Author
-
Veta M, Heng YJ, Stathonikos N, Bejnordi BE, Beca F, Wollmann T, Rohr K, Shah MA, Wang D, Rousson M, Hedlund M, Tellez D, Ciompi F, Zerhouni E, Lanyi D, Viana M, Kovalev V, Liauchuk V, Phoulady HA, Qaiser T, Graham S, Rajpoot N, Sjöblom E, Molin J, Paeng K, Hwang S, Park S, Jia Z, Chang EI, Xu Y, Beck AH, van Diest PJ, and Pluim JPW
- Subjects
- Biomarkers, Tumor genetics, Breast Neoplasms genetics, Cell Proliferation, Female, Gene Expression, Humans, Mitosis, Pathology methods, Predictive Value of Tests, Prognosis, Biomarkers, Tumor analysis, Breast Neoplasms pathology, Deep Learning, Image Processing, Computer-Assisted methods
- Abstract
Tumor proliferation is an important biomarker indicative of the prognosis of breast cancer patients. Assessment of tumor proliferation in a clinical setting is a highly subjective and labor-intensive task. Previous efforts to automate tumor proliferation assessment by image analysis only focused on mitosis detection in predefined tumor regions. However, in a real-world scenario, automatic mitosis detection should be performed in whole-slide images (WSIs) and an automatic method should be able to produce a tumor proliferation score given a WSI as input. To address this, we organized the TUmor Proliferation Assessment Challenge 2016 (TUPAC16) on prediction of tumor proliferation scores from WSIs. The challenge dataset consisted of 500 training and 321 testing breast cancer histopathology WSIs. In order to ensure fair and independent evaluation, only the ground truth for the training dataset was provided to the challenge participants. The first task of the challenge was to predict mitotic scores, i.e., to reproduce the manual method of assessing tumor proliferation by a pathologist. The second task was to predict the gene expression based PAM50 proliferation scores from the WSI. The best performing automatic method for the first task achieved a quadratic-weighted Cohen's kappa score of κ = 0.567, 95% CI [0.464, 0.671] between the predicted scores and the ground truth. For the second task, the predictions of the top method had a Spearman's correlation coefficient of r = 0.617, 95% CI [0.581 0.651] with the ground truth. This was the first comparison study that investigated tumor proliferation assessment from WSIs. The achieved results are promising given the difficulty of the tasks and weakly-labeled nature of the ground truth. However, further research is needed to improve the practical utility of image analysis methods for this task., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
21. SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression.
- Author
-
Zhang J, Chen M, Zhu Y, Dai X, Dang F, Ren J, Ren S, Shulga YV, Beca F, Gan W, Wu F, Lin YM, Zhou X, DeCaprio JA, Beck AH, Lu KP, Huang J, Zhao C, Sun Y, Gao X, Pandolfi PP, and Wei W
- Subjects
- Cullin Proteins metabolism, Disease Progression, Humans, Kruppel-Like Factor 4, Male, Mutation genetics, Nuclear Proteins genetics, Prostatic Neoplasms genetics, Prostatic Neoplasms pathology, Protein Interaction Domains and Motifs genetics, Repressor Proteins genetics, Ubiquitination, Cell Proliferation physiology, Nuclear Proteins metabolism, Prostatic Neoplasms metabolism, Repressor Proteins metabolism, Stem Cells cytology
- Abstract
Frequent SPOP mutation defines the molecular feature underlying one of seven sub-types of human prostate cancer (PrCa). However, it remains largely elusive how SPOP functions as a tumor suppressor in PrCa. Here, we report that SPOP suppresses stem cell traits of both embryonic stem cells and PrCa cells through promoting Nanog poly-ubiquitination and subsequent degradation. Mechanistically, Nanog, but not other pluripotency-determining factors including Oct4, Sox2, and Klf4, specifically interacts with SPOP via a conservative degron motif. Importantly, cancer-derived mutations in SPOP or at the Nanog-degron (S68Y) disrupt SPOP-mediated destruction of Nanog, leading to elevated cancer stem cell traits and PrCa progression. Notably, we identify the Pin1 oncoprotein as an upstream Nanog regulator that impairs its recognition by SPOP and thereby stabilizes Nanog. Thus, Pin1 inhibitors promote SPOP-mediated destruction of Nanog, which provides the molecular insight and rationale to use Pin1 inhibitor(s) for targeted therapies of PrCa patients with wild-type SPOP., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
22. Ancillary Tests in Breast Cytology: A Practical Guide.
- Author
-
Beca F and Schmitt FC
- Subjects
- Biopsy, Fine-Needle, Breast Neoplasms metabolism, Breast Neoplasms surgery, Female, Humans, Predictive Value of Tests, Biomarkers, Tumor metabolism, Breast Neoplasms diagnosis, Cytodiagnosis methods, Immunohistochemistry methods, Practice Guidelines as Topic standards
- Abstract
Utilization of fine-needle aspiration biopsy (FNAB) cytology for the diagnosis of diseases of the breast has been met with both excitement and uncertainty during the last couple of decades. Presently, FNAB for the diagnosis of primary and metastatic breast lesions is on the rise again. This is probably due to its fast turnaround time, cost efficiency, and minimal invasiveness, characteristics of this sampling modality which are particularly crucial for patients requiring frequent repeat biopsy in the setting of metastatic lesions. In this article, we will briefly review the main modern applications of FNAB of the breast when coupled with contemporary ancillary techniques. Such contemporary ancillary techniques range from classic immunocytochemistry (ICC) to the most modern molecular techniques, particularly next-generation sequencing. Coupled with contemporary ICC and molecular methods, FNAB of the breast can be used for several applications. The applications reviewed in this article include the primary diagnosis of a breast lesion, the identification of the breast as a primary source of a metastatic lesion, the evaluation of breast prognostic/predictive markers, and the tracking of tumor evolution. In our opinion, FNAB of the breast is an ideal sampling method, sharing many of the advantages of truly liquid and of tissue biopsies. Ultimately, we aim at demystifying the complexity of many of the challenges traditionally associated with the application of ancillary techniques to FNAB of the breast and provide insights into some of the most cutting-edge and clinically useful application scenarios., (© 2019 S. Karger AG, Basel.)
- Published
- 2019
- Full Text
- View/download PDF
23. Androgen receptor expression in normal breast tissue and subsequent breast cancer risk.
- Author
-
Kensler KH, Beca F, Baker GM, Heng YJ, Beck AH, Schnitt SJ, Hazra A, Rosner BA, Eliassen AH, Hankinson SE, Brown M, and Tamimi RM
- Abstract
Sex steroid hormone signaling is critical in the development of breast cancers, although the role of the androgen receptor remains unclear. This study evaluated androgen receptor (AR) expression in normal breast tissue as a potential marker of breast cancer risk. We conducted a nested case-control study of women with benign breast disease (BBD) within the Nurses' Health Studies. Epithelial AR expression was assessed by immunohistochemistry in normal tissue from the BBD biopsy and the percent of positive nuclei was estimated in ordinal categories of 10% for 78 breast cancer cases and 276 controls. Logistic regression models adjusting for the matching factors and BBD lesion type were used to calculate odds ratios (ORs) for the association between AR expression (tertiles: ≤10%, 11-30%, and >30%) and breast cancer risk. AR expression in normal breast tissue was not associated with subsequent breast cancer risk (OR
T3vsT1 = 0.9, 95% CI = 0.4-1.8, p trend = 0.68). In comparison with low AR/low ER women, ORs of 0.4 (95% CI = 0.1-1.2) for high AR/high ER women, 1.8 (95% CI = 0.4-7.8) for low AR/high ER women, and 0.7 (95% CI = 0.3-1.6) for high AR/low ER women were observed ( p interaction = 0.21). Ki67 did not modify the association between AR expression and breast cancer risk ( p interaction = 0.75). There was little evidence for an overall association between AR expression in normal breast tissue and breast cancer risk. These findings did not show that the AR association varied by Ki67 expression in normal breast tissue, though there was suggestive heterogeneity by ER expression., Competing Interests: A.H.B. is the co-founder and CEO of PathAI, Inc. The remaining authors declare no competing interests.- Published
- 2018
- Full Text
- View/download PDF
24. Diagnostic Assessment of Deep Learning Algorithms for Detection of Lymph Node Metastases in Women With Breast Cancer.
- Author
-
Ehteshami Bejnordi B, Veta M, Johannes van Diest P, van Ginneken B, Karssemeijer N, Litjens G, van der Laak JAWM, Hermsen M, Manson QF, Balkenhol M, Geessink O, Stathonikos N, van Dijk MC, Bult P, Beca F, Beck AH, Wang D, Khosla A, Gargeya R, Irshad H, Zhong A, Dou Q, Li Q, Chen H, Lin HJ, Heng PA, Haß C, Bruni E, Wong Q, Halici U, Öner MÜ, Cetin-Atalay R, Berseth M, Khvatkov V, Vylegzhanin A, Kraus O, Shaban M, Rajpoot N, Awan R, Sirinukunwattana K, Qaiser T, Tsang YW, Tellez D, Annuscheit J, Hufnagl P, Valkonen M, Kartasalo K, Latonen L, Ruusuvuori P, Liimatainen K, Albarqouni S, Mungal B, George A, Demirci S, Navab N, Watanabe S, Seno S, Takenaka Y, Matsuda H, Ahmady Phoulady H, Kovalev V, Kalinovsky A, Liauchuk V, Bueno G, Fernandez-Carrobles MM, Serrano I, Deniz O, Racoceanu D, and Venâncio R
- Subjects
- Algorithms, Female, Humans, Lymphatic Metastasis pathology, Pathology, Clinical, ROC Curve, Breast Neoplasms pathology, Lymphatic Metastasis diagnosis, Machine Learning, Pathologists
- Abstract
Importance: Application of deep learning algorithms to whole-slide pathology images can potentially improve diagnostic accuracy and efficiency., Objective: Assess the performance of automated deep learning algorithms at detecting metastases in hematoxylin and eosin-stained tissue sections of lymph nodes of women with breast cancer and compare it with pathologists' diagnoses in a diagnostic setting., Design, Setting, and Participants: Researcher challenge competition (CAMELYON16) to develop automated solutions for detecting lymph node metastases (November 2015-November 2016). A training data set of whole-slide images from 2 centers in the Netherlands with (n = 110) and without (n = 160) nodal metastases verified by immunohistochemical staining were provided to challenge participants to build algorithms. Algorithm performance was evaluated in an independent test set of 129 whole-slide images (49 with and 80 without metastases). The same test set of corresponding glass slides was also evaluated by a panel of 11 pathologists with time constraint (WTC) from the Netherlands to ascertain likelihood of nodal metastases for each slide in a flexible 2-hour session, simulating routine pathology workflow, and by 1 pathologist without time constraint (WOTC)., Exposures: Deep learning algorithms submitted as part of a challenge competition or pathologist interpretation., Main Outcomes and Measures: The presence of specific metastatic foci and the absence vs presence of lymph node metastasis in a slide or image using receiver operating characteristic curve analysis. The 11 pathologists participating in the simulation exercise rated their diagnostic confidence as definitely normal, probably normal, equivocal, probably tumor, or definitely tumor., Results: The area under the receiver operating characteristic curve (AUC) for the algorithms ranged from 0.556 to 0.994. The top-performing algorithm achieved a lesion-level, true-positive fraction comparable with that of the pathologist WOTC (72.4% [95% CI, 64.3%-80.4%]) at a mean of 0.0125 false-positives per normal whole-slide image. For the whole-slide image classification task, the best algorithm (AUC, 0.994 [95% CI, 0.983-0.999]) performed significantly better than the pathologists WTC in a diagnostic simulation (mean AUC, 0.810 [range, 0.738-0.884]; P < .001). The top 5 algorithms had a mean AUC that was comparable with the pathologist interpreting the slides in the absence of time constraints (mean AUC, 0.960 [range, 0.923-0.994] for the top 5 algorithms vs 0.966 [95% CI, 0.927-0.998] for the pathologist WOTC)., Conclusions and Relevance: In the setting of a challenge competition, some deep learning algorithms achieved better diagnostic performance than a panel of 11 pathologists participating in a simulation exercise designed to mimic routine pathology workflow; algorithm performance was comparable with an expert pathologist interpreting whole-slide images without time constraints. Whether this approach has clinical utility will require evaluation in a clinical setting.
- Published
- 2017
- Full Text
- View/download PDF
25. Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition.
- Author
-
Gil Del Alcazar CR, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F, Zi X, Kwak M, Bergholtz H, Su Y, Ding L, Russnes HG, Richardson AL, Babski K, Min Hui Kim E, McDonnell CH 3rd, Wagner J, Rowberry R, Freeman GJ, Dillon D, Sorlie T, Coussens LM, Garber JE, Fan R, Bobolis K, Allred DC, Jeong J, Park SY, Michor F, and Polyak K
- Subjects
- B7-H1 Antigen genetics, Biomarkers, Tumor genetics, Breast Neoplasms genetics, CD3 Complex genetics, Carcinoma, Ductal, Breast genetics, Carcinoma, Intraductal, Noninfiltrating genetics, Disease Progression, Female, Gene Expression Regulation, Neoplastic, Humans, Leukocyte Common Antigens genetics, Receptor, ErbB-2 genetics, Tumor Microenvironment, Breast Neoplasms immunology, Carcinoma, Ductal, Breast immunology, Carcinoma, Intraductal, Noninfiltrating immunology, Gene Expression Profiling methods, T-Lymphocytes immunology
- Abstract
To investigate immune escape during breast tumor progression, we analyzed the composition of leukocytes in normal breast tissues, ductal carcinoma in situ (DCIS), and invasive ductal carcinomas (IDC). We found significant tissue and tumor subtype-specific differences in multiple cell types including T cells and neutrophils. Gene expression profiling of CD45
+ CD3+ T cells demonstrated a decrease in CD8+ signatures in IDCs. Immunofluorescence analysis showed fewer activated GZMB+ CD8+ T cells in IDC than in DCIS, including in matched DCIS and recurrent IDC. T-cell receptor clonotype diversity was significantly higher in DCIS than in IDCs. Immune checkpoint protein TIGIT-expressing T cells were more frequent in DCIS, whereas high PD-L1 expression and amplification of CD274 (encoding PD-L1) was only detected in triple-negative IDCs. Coamplification of a 17q12 chemokine cluster with ERBB2 subdivided HER2+ breast tumors into immunologically and clinically distinct subtypes. Our results show coevolution of cancer cells and the immune microenvironment during tumor progression. Significance: The design of effective cancer immunotherapies requires the understanding of mechanisms underlying immune escape during tumor progression. Here we demonstrate a switch to a less active tumor immune environment during the in situ to invasive breast carcinoma transition, and identify immune regulators and genomic alterations that shape tumor evolution. Cancer Discov; 7(10); 1098-115. ©2017 AACR. See related commentary by Speiser and Verdeil, p. 1062 This article is highlighted in the In This Issue feature, p. 1047 ., (©2017 American Association for Cancer Research.)- Published
- 2017
- Full Text
- View/download PDF
26. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
- Author
-
Dai X, Gan W, Li X, Wang S, Zhang W, Huang L, Liu S, Zhong Q, Guo J, Zhang J, Chen T, Shimizu K, Beca F, Blattner M, Vasudevan D, Buckley DL, Qi J, Buser L, Liu P, Inuzuka H, Beck AH, Wang L, Wild PJ, Garraway LA, Rubin MA, Barbieri CE, Wong KK, Muthuswamy SK, Huang J, Chen Y, Bradner JE, and Wei W
- Subjects
- Apoptosis, Azepines, Benzodiazepines, Cell Cycle Proteins, Cell Proliferation, Cullin Proteins, HEK293 Cells, HeLa Cells, Humans, Immunoblotting, Immunoprecipitation, Male, Molecular Targeted Therapy, Prostatic Neoplasms drug therapy, Prostatic Neoplasms metabolism, Protein Serine-Threonine Kinases, RNA-Binding Proteins, Thalidomide analogs & derivatives, Triazoles, Ubiquitination, Drug Resistance, Neoplasm genetics, Nuclear Proteins genetics, Nuclear Proteins metabolism, Prostatic Neoplasms genetics, Repressor Proteins genetics, Transcription Factors metabolism
- Abstract
The bromodomain and extraterminal (BET) family of proteins comprises four members-BRD2, BRD3, BRD4 and the testis-specific isoform BRDT-that largely function as transcriptional coactivators and play critical roles in various cellular processes, including the cell cycle, apoptosis, migration and invasion. BET proteins enhance the oncogenic functions of major cancer drivers by elevating the expression of these drivers, such as c-Myc in leukemia, or by promoting the transcriptional activities of oncogenic factors, such as AR and ERG in prostate cancer. Pathologically, BET proteins are frequently overexpressed and are clinically linked to various types of human cancer; they are therefore being pursued as attractive therapeutic targets for selective inhibition in patients with cancer. To this end, a number of bromodomain inhibitors, including JQ1 and I-BET, have been developed and have shown promising outcomes in early clinical trials. Although resistance to BET inhibitors has been documented in preclinical models, the molecular mechanisms underlying acquired resistance are largely unknown. Here we report that cullin-3
SPOP earmarks BET proteins, including BRD2, BRD3 and BRD4, for ubiquitination-mediated degradation. Pathologically, prostate cancer-associated SPOP mutants fail to interact with and promote the degradation of BET proteins, leading to their elevated abundance in SPOP-mutant prostate cancer. As a result, prostate cancer cell lines and organoids derived from individuals harboring SPOP mutations are more resistant to BET-inhibitor-induced cell growth arrest and apoptosis. Therefore, our results elucidate the tumor-suppressor role of SPOP in prostate cancer in which it acts as a negative regulator of BET protein stability and also provide a molecular mechanism for resistance to BET inhibitors in individuals with prostate cancer bearing SPOP mutations.- Published
- 2017
- Full Text
- View/download PDF
27. EZH2 protein expression in normal breast epithelium and risk of breast cancer: results from the Nurses' Health Studies.
- Author
-
Beca F, Kensler K, Glass B, Schnitt SJ, Tamimi RM, and Beck AH
- Subjects
- Adult, Biomarkers, Tumor, Biopsy, Case-Control Studies, Enhancer of Zeste Homolog 2 Protein genetics, Epithelium pathology, Female, Gene Expression, Humans, Immunohistochemistry, Ki-67 Antigen metabolism, Mammary Glands, Human pathology, Middle Aged, Neoplasm Grading, Nurses, Odds Ratio, Population Surveillance, Prognosis, Receptors, Estrogen metabolism, Risk, Breast Neoplasms epidemiology, Breast Neoplasms etiology, Enhancer of Zeste Homolog 2 Protein metabolism, Epithelium metabolism, Mammary Glands, Human metabolism
- Abstract
Background: Enhancer of zeste homolog 2 (EZH2) is a polycomb-group protein that is involved in stem cell renewal and carcinogenesis. In breast cancer, increased EZH2 expression is associated with aggressiveness and has been suggested to identify normal breast epithelium at increased risk of breast cancer development. However, the association between EZH2 expression in benign breast tissue and breast cancer risk has not previously been evaluated in a large prospective cohort., Methods: We examined the association between EZH2 protein expression and subsequent breast cancer risk using logistic regression in a nested case-control study of benign breast disease (BBD) and breast cancer within the Nurses' Health Studies. EZH2 immunohistochemical expression in normal breast epithelium and stroma was evaluated by computational image analysis and its association with breast cancer risk was analyzed after adjusting for matching factors between cases and controls, the concomitant BBD diagnosis, and the Ki67 proliferation index., Results: Women with a breast biopsy in which more than 20% of normal epithelial cells expressed EZH2 had a significantly increased risk of developing breast cancer (odds ratio (OR) 2.95, 95% confidence interval (CI) 1.11-7.84) compared to women with less than 10% EZH2 epithelial expression. The risk of developing breast cancer increased for each 5% increase in EZH2 expression (OR 1.22, 95% CI 1.02-1.46, p value 0.026). Additionally, women with high EZH2 expression and low estrogen receptor (ER) expression had a 4-fold higher risk of breast cancer compared to women with low EZH2 and low ER expression (OR 4.02, 95% CI 1.29-12.59)., Conclusions: These results provide further evidence that EZH2 expression in the normal breast epithelium is independently associated with breast cancer risk and might be used to assist in risk stratification for women with benign breast biopsies.
- Published
- 2017
- Full Text
- View/download PDF
28. Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling.
- Author
-
Henry WS, Laszewski T, Tsang T, Beca F, Beck AH, McAllister SS, and Toker A
- Subjects
- AMP-Activated Protein Kinases metabolism, Animals, Breast Neoplasms genetics, Breast Neoplasms metabolism, Cell Line, Tumor, Class I Phosphatidylinositol 3-Kinases, Female, Gene Knockdown Techniques, Humans, Immunoblotting, Mechanistic Target of Rapamycin Complex 1, Mice, Mice, Inbred NOD, Mice, Transgenic, Multiprotein Complexes metabolism, Phosphatidylinositol 3-Kinases genetics, Polymerase Chain Reaction, TOR Serine-Threonine Kinases metabolism, Xenograft Model Antitumor Assays, Anti-Inflammatory Agents, Non-Steroidal pharmacology, Aspirin pharmacology, Breast Neoplasms pathology, Cell Proliferation drug effects, Signal Transduction drug effects
- Abstract
Despite the high incidence of oncogenic mutations in PIK3CA, the gene encoding the catalytic subunit of PI3K, PI3K inhibitors have yielded little clinical benefit for breast cancer patients. Recent epidemiologic studies have suggested a therapeutic benefit from aspirin intake in cancers harboring oncogenic PIK3CA Here, we show that mutant PIK3CA-expressing breast cancer cells have greater sensitivity to aspirin-mediated growth suppression than their wild-type counterparts. Aspirin decreased viability and anchorage-independent growth of mutant PIK3CA breast cancer cells independently of its effects on COX-2 and NF-κB. We ascribed the effects of aspirin to AMP-activated protein kinase (AMPK) activation, mTORC1 inhibition, and autophagy induction. In vivo, oncogenic PIK3CA-driven mouse mammary tumors treated daily with aspirin resulted in decreased tumor growth kinetics, whereas combination therapy of aspirin and a PI3K inhibitor further attenuated tumor growth. Our study supports the evaluation of aspirin and PI3K pathway inhibitors as a combination therapy for targeting breast cancer. Cancer Res; 77(3); 790-801. ©2016 AACR., Competing Interests: The authors disclose no potential conflict of interest, (©2016 American Association for Cancer Research.)
- Published
- 2017
- Full Text
- View/download PDF
29. LINC00520 is induced by Src, STAT3, and PI3K and plays a functional role in breast cancer.
- Author
-
Henry WS, Hendrickson DG, Beca F, Glass B, Lindahl-Allen M, He L, Ji Z, Struhl K, Beck AH, Rinn JL, and Toker A
- Subjects
- Breast Neoplasms genetics, Breast Neoplasms pathology, Cell Movement, Cell Proliferation, Cell Transformation, Neoplastic genetics, Cell Transformation, Neoplastic metabolism, Cell Transformation, Neoplastic pathology, Class I Phosphatidylinositol 3-Kinases genetics, Female, Gene Expression Regulation, Neoplastic, Humans, MCF-7 Cells, Mammary Glands, Human enzymology, Mammary Glands, Human pathology, Mutation, Neoplasm Invasiveness, Oncogene Protein pp60(v-src) genetics, Oncogene Protein pp60(v-src) metabolism, RNA Interference, RNA, Long Noncoding genetics, STAT3 Transcription Factor genetics, Signal Transduction, Time Factors, Transfection, Up-Regulation, Breast Neoplasms enzymology, Class I Phosphatidylinositol 3-Kinases metabolism, RNA, Long Noncoding metabolism, STAT3 Transcription Factor metabolism
- Abstract
Long non-coding RNAs (lncRNAs) have been implicated in normal cellular homeostasis as well as pathophysiological conditions, including cancer. Here we performed global gene expression profiling of mammary epithelial cells transformed by oncogenic v-Src, and identified a large subset of uncharacterized lncRNAs potentially involved in breast cancer development. Specifically, our analysis revealed a novel lncRNA, LINC00520 that is upregulated upon ectopic expression of oncogenic v-Src, in a manner that is dependent on the transcription factor STAT3. Similarly, LINC00520 is also increased in mammary epithelial cells transformed by oncogenic PI3K and its expression is decreased upon knockdown of mutant PIK3CA. Additional expression profiling highlight that LINC00520 is elevated in a subset of human breast carcinomas, with preferential enrichment in the basal-like molecular subtype. ShRNA-mediated depletion of LINC00520 results in decreased cell migration and loss of invasive structures in 3D. RNA sequencing analysis uncovers several genes that are differentially expressed upon ectopic expression of LINC00520, a significant subset of which are also induced in v-Src-transformed MCF10A cells. Together, these findings characterize LINC00520 as a lncRNA that is regulated by oncogenic Src, PIK3CA and STAT3, and which may contribute to the molecular etiology of breast cancer.
- Published
- 2016
- Full Text
- View/download PDF
30. Precision Cancer Diagnostics: Tracking Genomic Evolution in Clinical Trials.
- Author
-
Beca F and Beck AH
- Subjects
- Breast Neoplasms diagnosis, Clinical Trials, Phase II as Topic, Female, Humans, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Evolution, Molecular, Genome
- Abstract
In a Perspective, Francisco Beca and Andrew Beck discuss Charles Swanton and colleagues' accompanying Research Article on somatic mutations in patients with inflammatory breast cancer treated in a Phase II clinical trial., Competing Interests: I have read the journal's policy and have the following conflicts: AHB is a co-founder and equity holder in PathAI, Inc. At the time of writing, AHB received a stipend as a specialty consulting editor for PLOS Medicine and served on the journal's editorial board.
- Published
- 2016
- Full Text
- View/download PDF
31. MicroRNA signatures in cytopathology: Are they ready for prime time?
- Author
-
Beca F and Schmitt F
- Subjects
- Humans, Prognosis, Biomarkers, Tumor genetics, Cytodiagnosis methods, MicroRNAs genetics, Neoplasms diagnosis, Neoplasms genetics
- Published
- 2016
- Full Text
- View/download PDF
32. Intratumor Heterogeneity in Breast Cancer.
- Author
-
Beca F and Polyak K
- Subjects
- Animals, Breast Neoplasms drug therapy, Breast Neoplasms metabolism, Breast Neoplasms mortality, Breast Neoplasms pathology, Drug Resistance, Neoplasm genetics, Epigenesis, Genetic, Female, Gene Expression Regulation, Neoplastic, Genetic Predisposition to Disease, Genetic Testing, Humans, Patient Selection, Phenotype, Precision Medicine, Predictive Value of Tests, Prognosis, Risk Assessment, Risk Factors, Biomarkers, Tumor genetics, Breast Neoplasms genetics, Genetic Variation
- Abstract
Intratumor heterogeneity is the main obstacle to effective cancer treatment and personalized medicine. Both genetic and epigenetic sources of intratumor heterogeneity are well recognized and several technologies have been developed for their characterization. With the technological advances in recent years, investigators are now elucidating intratumor heterogeneity at the single cell level and in situ. However, translating the accumulated knowledge about intratumor heterogeneity to clinical practice has been slow. We are certain that better understanding of the composition and evolution of tumors during disease progression and treatment will improve cancer diagnosis and the design of therapies. Here we review some of the most important considerations related to intratumor heterogeneity. We discuss both genetic and epigenetic sources of intratumor heterogeneity and review experimental approaches that are commonly used to quantify it. We also discuss the impact of intratumor heterogeneity on cancer diagnosis and treatment and share our perspectives on the future of this field.
- Published
- 2016
- Full Text
- View/download PDF
33. Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer.
- Author
-
Beca F, Pereira M, Cameselle-Teijeiro JF, Martins D, and Schmitt F
- Subjects
- Adult, Aged, Breast Neoplasms genetics, Breast Neoplasms metabolism, Female, Gene Deletion, Gene Dosage, Humans, Middle Aged, Prognosis, Retrospective Studies, Survival Analysis, Breast Neoplasms pathology, Cyclin D1 genetics, Cyclin D1 metabolism, Protein Phosphatase 2 genetics, Protein Phosphatase 2 metabolism
- Abstract
Background: PPP2R2A deletions were recently linked to a subgroup of luminal breast carcinoma (BC) that exhibits poor survival. This subgroup also exhibited amplification of a chromosome region containing the Cyclin D1 coding gene, CCND1. Therefore, we aimed to investigate whether a combination of PPP2R2A (B55α) and Cyclin D1 expression statuses evaluated by immunohistochemistry (IHC) could define a subgroup of luminal BC that exhibits poor survival., Methods: First we conducted a retrospective cohort study using sequencing data from The Cancer Genome Atlas initiative to correlate PPP2R2A copy number alteration (CNA) status with its expression level and the corresponding overall survival (OS). Next, also using a retrospective cohort study design, we evaluated the PPP2R2A (B55α) expression levels by IHC in a total of 807 BC patients from two independent cohorts (discovery cohort n = 349 and validation cohort n = 458). Cyclin D1 expression was also evaluated, and the PPP2R2A (B55α)(-/low)/Cyclin D1(high) phenotype was evaluated as a predictor of disease-free survival (DFS) and OS in luminal-like BC patients., Results: Deletions in the PPP2R2A gene strongly correlate with lower mRNA expression and poorer OS. PPP2R2A (B55α)(-/low) carcinomas have significantly shorter DFS and OS. Furthermore, in univariate analysis, the PPP2R2A (B55α)(-/low)/Cyclin D1(high) phenotype is significantly associated with poorer DFS and OS. In a multivariate analysis, the PPP2R2A (B55α)(-/low)/Cyclin D1(high) phenotype is significantly associated with poor DFS, thus defining a group of luminal-like BC with higher risk of relapse., Conclusion: We demonstrate that BCs harboring PPP2R2A deletions are associated with worse OS. Moreover, this is the first study to demonstrate that the combination of altered PPP2R2A (B55α) and high Cyclin D1 expression by IHC defines a subgroup of luminal-like BC patients with a high risk of relapse and death.
- Published
- 2015
- Full Text
- View/download PDF
34. Genotypes and prevalence of HPV single and multiple concurrent infections in women with HSIL.
- Author
-
Beca F, Pinheiro J, Rios E, Pontes P, and Amendoeira I
- Subjects
- Adult, Coinfection diagnosis, Coinfection epidemiology, Cross-Sectional Studies, Female, Genotype, Human Papillomavirus DNA Tests, Humans, Middle Aged, Papillomavirus Infections diagnosis, Papillomavirus Infections epidemiology, Prevalence, Squamous Intraepithelial Lesions of the Cervix diagnosis, Squamous Intraepithelial Lesions of the Cervix epidemiology, Coinfection virology, Human papillomavirus 16 genetics, Papillomavirus Infections virology, Squamous Intraepithelial Lesions of the Cervix virology
- Abstract
The contribution of human papillomavirus (HPV) types to the carcinogenesis of cervical cancer has been established for a long time. However, the role of phylogenetically related and rare variants remains uncertain, as well as the influence of concurrent multiple HPV genotypes infection. We aimed at studying the prevalence of several HPV genotypes infecting women with single versus concurrent multiple HPV genotypes infection with a HSIL diagnosis in a cervical cytology. We conducted a cross-sectional study using Thin-Prep(®) liquid-based cervical cytology specimens with the diagnosis of high-grade squamous intraepithelial lesion (HSIL), in which HPV genotype was sequentially tested. Genotypes were determined with a PapilloCheck(®) system, a DNA-Chip for the type-specific identification of 18 high-risk and six low-risk types of HPV. Of the total study population, 176 cases had a diagnosis of HSIL and positive HPV genotyping result, being HPV16 the most prevalent genotype (48.86%; 95%CI: 41.58-56.19) followed by HPV31 (14.20%; 95%CI: 9.75-20.18). Concurrent multiple HPV genotypes were detected in 36.93% (95%CI: 30.15-44.27) of the patients. The prevalence of the 10 most common HPV genotypes detected varied significantly according to the presence of single vs. concurrent multiple HPV genotypes (P = 0.022). Moreover, women with concurrent multiple HPV genotypes were on average 3.53 (95%CI: 0.43-6.64) years younger than women with single genotype infection. Our results suggest that women with multiple genotype HPV infection differ in terms of age and distribution of the most prevalent HPV genotypes. Additionally, we provide further evidence of the predominance of HPV16 in HSIL lesions of the uterine cervix., (© 2014 Wiley Periodicals, Inc.)
- Published
- 2014
- Full Text
- View/download PDF
35. p-mTOR expression is associated with better prognosis in luminal breast carcinoma.
- Author
-
Beca F, Andre R, Martins DS, Bilhim T, Martins D, and Schmitt F
- Subjects
- Biopsy, Breast Neoplasms mortality, Breast Neoplasms pathology, Carcinoma mortality, Carcinoma pathology, Chi-Square Distribution, Disease Progression, Disease-Free Survival, Female, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Lymphatic Metastasis, Middle Aged, Multivariate Analysis, Neoplasm Grading, Phosphorylation, Predictive Value of Tests, Proportional Hazards Models, Retrospective Studies, Risk Factors, Time Factors, Tissue Array Analysis, Tumor Burden, Biomarkers, Tumor analysis, Breast Neoplasms enzymology, Carcinoma enzymology, TOR Serine-Threonine Kinases analysis
- Abstract
Aims: Despite considerable interest in the PI3K/AKT/mTOR pathway in breast carcinomas (BC), published data reports contradictory results regarding the association of phosphorylated mammalian target of Rapamycin (p-mTOR) expression with clinico-pathological features and prognosis in BC. Here, we evaluate the main clinico-pathological associations with p-mTOR expression in BC, with focus on the different molecular subtypes., Methods: In this retrospective study, 331 BC patients were included in final analysis. Outcome measures included disease-free survival (DFS) and overall survival (OS) times. Baseline data and outcome measures were compared between immunohistochemical p-mTOR expressing and non-expressing BCs. Subgroup analysis was performed to assess the effect of p-mTOR expression in the outcome for each BC molecular subtype., Results: 43.8% of the tumours were positive for p-mTOR, with a significant correlation between p-mTOR expression with smaller (<2 cm) (p=0.021) and lower-grade tumours (p<0.001). Expression of p-mTOR was also associated with longer DFS (HR of 0.32, p<0.001) and OS (HR of 0.20, p<0.001). In a multivariable analysis, the HR remained significant with minimal change (HR=0.26, p=0.002 for OS; HR=0.40, p=0.002 for DFS). In subgroup analysis, luminal p-mTOR-expressing tumours demonstrated longer DFS and OS (HR 0.33, p=0.003; HR 0.20, p=0.003, respectively) independently of size, grade, lymph node status and Her-2 overexpression., Conclusions: p-mTOR expression is associated with smaller, lower-grade and with luminal BC. In multivariable analysis, p-mTOR expression was associated with longer DFS and OS, independently of the size, grade and lymph node status, especially in luminal BCs., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.)
- Published
- 2014
- Full Text
- View/download PDF
36. Tumor heterogeneity: the Lernaean hydra of oncology?
- Author
-
Janiszewska M, Beca F, and Polyak K
- Subjects
- Humans, Biomarkers, Tumor genetics, DNA, Neoplasm genetics, Genetic Heterogeneity, Genetic Predisposition to Disease, Neoplasms classification, Neoplasms genetics
- Published
- 2014
37. Primary relapse site pattern in women with triple-negative breast cancer.
- Author
-
Beca F, Santos R, Vieira D, Zeferino L, Dufloth R, and Schmitt F
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Middle Aged, Carcinoma pathology, Neoplasm Metastasis pathology, Neoplasm Recurrence, Local pathology, Triple Negative Breast Neoplasms pathology
- Abstract
Despite the remarkable improvements in breast cancer (BC) characterization, accurate prediction of BC clinical behavior is often still difficult to achieve. Some studies have investigated the association between the molecular subtype, namely the basal-like BC and the pattern of relapse, however only few investigated the association between relapse pattern and immunohistochemical defined triple-negative breast cancers (TNBCs). The aim of this study was to evaluate the pattern of relapse in patients with TNBC, namely the primary distant relapse site. One-hundred twenty nine (129) invasive breast carcinomas with follow-up information were classified according to the molecular subtype using immunohistochemistry for ER, PgR and Her2. The association between TNBC and distant relapse primary site was analyzed by logistic regression. Using multivariate logistic regression analysis patients with TNBC displayed only 0.09 (95% CI: 0.00-0.74; p=0.02) the odds of the non-TNBC patients of developing bone primary relapse. Regarding visceral and lymph-node relapse, no differences between in this cohort were found. Though classically regarded as aggressive tumors, TNBCs rarely development primary relapse in bone when compared to non-TNBC, a clinical relevant fact when investigating a metastasis of an occult or non-sampled primary BC., (Copyright © 2014 Elsevier GmbH. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
38. Growing indication for FNA to study and analyze tumor heterogeneity at metastatic sites.
- Author
-
Beca F and Schmitt F
- Subjects
- Humans, Biopsy, Needle statistics & numerical data, Neoplasm Metastasis, Neoplasms pathology
- Abstract
In routine practice, suspected metastases in patients with cancer are only occasionally biopsied, primarily because of the cost and invasiveness of the procedure. However, biopsies of metastatic lesions can be valuable, not only in confirming the presence of metastatic disease, but also in revealing unsuspected benign disease or secondary malignancies. In addition, such biopsies also allow the assessment of biomarkers that might differ from those on primary tumor cells, and can thereby facilitate selection of the optimal treatment. Because of the increasing recognition of clonal and phenotypic heterogeneity of tumors, we anticipate that in the near future, biopsying of metastatic lesions will constitute a standard-of-care practice, allowing assessment of molecular differences between the primary tumor and metastatic lesions. In our opinion, fine-needle aspiration is currently the best method for making repeated biopsies to monitor the tumor: it is minimally invasive, safe, and cost effective and can be coupled with modern ancillary techniques. Here we provide an up-to-date review of the clinical implications of tumor heterogeneity in metastatic disease and the ancillary molecular techniques used in cytology; we also discuss the role of modern cytology in contemporary diagnosis and management of metastatic cancer., (© 2014 American Cancer Society.)
- Published
- 2014
- Full Text
- View/download PDF
39. [Latest news on management of lower back pain].
- Author
-
Cano Martínez S, Moyano De BeCa F, Vila Longueira M, and Louro González A
- Subjects
- Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Exercise Therapy, Humans, Patient Satisfaction, Radiography, Rest, Low Back Pain diagnostic imaging, Low Back Pain therapy
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.